Skip to Content

Victrelis FDA Approval History

FDA Approved: Yes (Discontinued) (First approved May 13, 2011)
Brand name: Victrelis
Generic name: boceprevir
Company: Merck
Treatment for: Hepatitis C

Marketing Status: Discontinued

Victrelis (boceprevir) is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C.

Development Timeline for Victrelis

DateArticle
May 14, 2011ApprovalFDA Approves Merck's Victrelis (boceprevir), First-in-Class Oral Hepatitis C Virus (HCV) Protease Inhibitor
Apr 28, 2011Victrelis (boceprevir) Unanimously Recommended for Approval By FDA Advisory Committee for Treatment of Chronic HCV Genotype 1 Infection
Jan  6, 2011Boceprevir, Merck's Investigational Oral Hepatitis C Protease Inhibitor, Receives FDA Priority Review and EMA Accelerated Assessment

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.